The cardiovascular physiology and pharmacology of endothelin-1

Advances in Pharmacology

Volumn 60, Issue C, 2010, Pages 1-26

  Thorin, Eric ^a   Clozel, Martine ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Bivalent ligand; Cardiomyocytes; Cardiovascular diseases; Dimers; Vasculature

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ACETYLCHOLINE; AMBRISENTAN; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR AGONIST; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; IRL 2500; MACITENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; RES 7011; S 6C; SITAXSENTAN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TBC 3711; UNCLASSIFIED DRUG; ZIBOTENTAN; ENDOTHELIN RECEPTOR;

ARTERY CONSTRICTION; BLOOD VESSEL TONE; BOOK; BRAIN CIRCULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; ENDOTHELIUM; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CIRCULATION; LUNG CIRCULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; VASODILATATION; ANIMAL; CARDIOVASCULAR FUNCTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; PHYSIOLOGY; REVIEW;

ANIMALS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; ENDOTHELIN-1; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 79952278675     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385061-4.00001-5     Document Type: Chapter

References (177)

1. Aird W.C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circulation Research 2007, 100:158-173.
2. Alexander S.P., Mathie A., Peters J.A. Guide to Receptors and Channels (GRAC), 4th edition. British Journal of Pharmacology 2009, 158(Suppl. 1):S42-S43.
3. Alonso D., Radomski M.W. The nitric oxide-endothelin-1 connection. Heart Failure Reviews 2003, 8:107-115.
4. Anggrahini D.W., Emoto N., Nakayama K., Widyantoro B., Adiarto S., Iwasa N., Nonaka H., Rikitake Y., Kisanuki Y.Y., Yanagisawa M., Hirata K. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovascular Research 2009, 82:143-151.
5. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
6. Aronson D., Burger A.J. Neurohormonal prediction of mortality following admission for decompensated heart failure. The American Journal of Cardiology 2003, 91:245-248.
7. Aronson D., Burger A.J. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: Role of endothelin. Pacing and Clinical Electrophysiology 2003, 26:703-710.
8. Aronson D., Mittleman M.A., Burger A.J. Role of endothelin in modulation of heart rate variability in patients with decompensated heart failure. Pacing and Clinical Electrophysiology 2001, 24:1607-1615.
9. Aubert J.D., Juillerat-Jeanneret L. Therapeutic potential of endothelin receptor modulators: Lessons from human clinical trials. Expert Opinion on Therapeutic Targets 2009, 13:1069-1084.
10. Bacon C.R., Cary N.R., Davenport A.P. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circulation Research 1996, 79:794-801.
11. Bacon C.R., Davenport A.P. Endothelin receptors in human coronary artery and aorta. British Journal of Pharmacology 1996, 117:986-992.
12. Bagnall A.J., Kelland N.F., Gulliver-Sloan F., Davenport A.P., Gray G.A., Yanagisawa M., Webb D.J., Kotelevtsev Y.V. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 2006, 48:286-293.
13. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., McLaughlin V., Hill N., Tapson V.F., Robbins I.M., Zwicke D., Duncan B., Dixon R.A., Frumkin L.R. Sitaxsentan therapy for pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 2004, 169:441-447.
14. Barton M., Haudenschild C.C., d'Uscio L.V., Shaw S., Munter K., Luscher T.F. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14367-14372.
15. Barton M., Yanagisawa M. Endothelin: 20 years from discovery to therapy. Canadian Journal of Physiology and Pharmacology 2008, 86:485-498.
16. Bergdahl A., Valdemarsson S., Adner M., Sun X.Y., Hedner T., Edvinsson L. Enhanced endothelin-1-induced contractions in mesenteric arteries from rats with congestive heart failure: Role of ET(B) receptors. European Journal of Heart Failure 2001, 3:293-299.
17. Bialecki R.A., Izzo N.J., Colucci W.S. Endothelin-1 increases intracellular calcium mobilization but not calcium uptake in rabbit vascular smooth muscle cells. Biochemical and Biophysical Research Communications 1989, 164:474-479.
18. Bkaily G., Choufani S., Hassan G., El-Bizri N., Jacques D., D'Orleans-Juste P. Presence of functional endothelin-1 receptors in nuclear membranes of human aortic vascular smooth muscle cells. Journal of Cardiovascular Pharmacology 2000, 36:S414-S417.
19. Bohm F., Jensen J., Svane B., Settergren M., Pernow J. Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Canadian Journal of Physiology and Pharmacology 2008, 86:745-751.
20. Boivin B., Chevalier D., Villeneuve L.R., Rousseau E., Allen B.G. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. The Journal of Biological Chemistry 2003, 278:29153-29163.
21. Boulanger C., Luscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. The Journal of Clinical Investigation 1990, 85:587-590.
22. Brunner F. Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology 1995, 27:1953-1963.
23. Brunner F., Bras-Silva C., Cerdeira A.S., Leite-Moreira A.F. Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis. Pharmacology & Therapeutics 2006, 111:508-531.
24. Brunner F., Stessel H., Kukovetz W.R. Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Letters 1995, 376:262-266.
25. Burrell K.M., Molenaar P., Dawson P.J., Kaumann A.J. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670. The Journal of Pharmacology and Experimental Therapeutics 2000, 292:449-459.
26. Callera G., Tostes R., Savoia C., Muscara M.N., Touyz R.M. Vasoactive peptides in cardiovascular (patho)physiology. Expert Review of Cardiovascular Therapy 2007, 5:531-552.
27. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Badesch D.B., Roux S., Rainisio M., Bodin F., Rubin L.J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
28. Chen C., Wagoner P.K. Endothelin induces a nonselective cation current in vascular smooth muscle cells. Circulation Research 1991, 69:447-454.
29. Clerk A., Bogoyevitch M.A., Anderson M.B., Sugden P.H. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. The Journal of Biological Chemistry 1994, 269:32848-32857.
30. Climent B., Fernandez N., Sanz E., Sanchez A., Monge L., Garcia-Villalon A.L., Dieguez G. Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. European Journal of Pharmacology 2005, 524:102-110.
31. Clozel M., Breu V., Burri K., Cassal J.M., Fischli W., Gray G.A., Hirth G., Loffler B.M., Muller M., Neidhart W., et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993, 365:759-761.
32. Clozel M., Gray G.A., Breu V., Loffler B.M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochemical and Biophysical Research Communications 1992, 186:867-873.
33. Dagassan P.H., Breu V., Clozel M., Kunzli A., Vogt P., Turina M., Kiowski W., Clozel J.P. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. Journal of Cardiovascular Pharmacology 1996, 27:147-153.
34. Dai X., Galligan J.J. Differential trafficking and desensitization of human ET(A) and ET(B) receptors expressed in HEK 293 cells. Experimental Biology and Medicine (Maywood) 2006, 231:746-751.
35. Dancu M.B., Tarbell J.M. Coronary endothelium expresses a pathologic gene pattern compared to aortic endothelium: Correlation of asynchronous hemodynamics and pathology in vivo. Atherosclerosis 2007, 192:9-14.
36. Dashwood M.R., Mehta D., Izzat M.B., Timm M., Bryan A.J., Angelini G.D., Jeremy J.Y. Distribution of endothelin-1 (ET) receptors (ET(A) and ET(B)) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis 1998, 137:233-242.
37. Dashwood M.R., Timm M., Muddle J.R., Ong A.C., Tippins J.R., Parker R., McManus D., Murday A.J., Madden B.P., Kaski J.C. Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: Pathophysiological implications in coronary disease. Endothelium 1998, 6:61-70.
38. Dashwood M.R., Tsui J.C. Endothelin-1 and atherosclerosis: Potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002, 160:297-304.
39. Davenport A.P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacological Reviews 2002, 54:219-226.
40. Davenport A.P., Maguire J.J. The endothelin system in human saphenous vein graft disease. Current Opinion in Pharmacology 2001, 1:176-182.
41. Davenport A.P., O'Reilly G., Molenaar P., Maguire J.J., Kuc R.E., Sharkey A., Bacon C.R., Ferro A. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: Evidence for expression of ETB receptors in human vascular smooth muscle. Journal of Cardiovascular Pharmacology 1993, 22(Suppl 8):S22-S25.
42. De Mey J.G., Vanhoutte P.M. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circulation Research 1982, 51:439-447.
43. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T.D., Vane J.R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:9797-9800.
44. Denault J.B., Claing A., D'Orleans-Juste P., Sawamura T., Kido T., Masaki T., Leduc R. Processing of proendothelin-1 by human furin convertase. FEBS Letters 1995, 362:276-280.
45. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. Journal of the American Society of Nephrology 2006, 17:943-955.
46. Dhaun N., Macintyre I.M., Melville V., Lilitkarntakul P., Johnston N.R., Goddard J., Webb D.J. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009, 54:113-119.
47. Docherty C.C., MacLean M.R. EndothelinB receptors in rabbit pulmonary resistance arteries: Effect of left ventricular dysfunction. The Journal of Pharmacology and Experimental Therapeutics 1998, 284:895-903.
48. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., Ohlstein E.H., Willette R.N. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 2000, 131:1262-1274.
49. Drake M.T., Violin J.D., Whalen E.J., Wisler J.W., Shenoy S.K., Lefkowitz R.J. beta-arrestin-biased agonism at the beta2-adrenergic receptor. The Journal of Biological Chemistry 2008, 283:5669-5676.
50. Dupuis J., Goresky C.A., Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. Journal of Applied Physiology 1996, 81:1510-1515.
51. Dupuis J., Goresky C.A., Rose C.P., Stewart D.J., Cernacek P., Schwab A.J., Simard A. Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo. The American Journal of Physiology 1997, 273:H1239-H1245.
52. Dupuis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584.
53. Evans N.J., Walker J.W. Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophysical Journal 2008, 95:483-492.
54. Evans N.J., Walker J.W. Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Canadian Journal of Physiology and Pharmacology 2008, 86:526-535.
55. Fan J., Unoki H., Iwasa S., Watanabe T. Role of endothelin-1 in atherosclerosis. Annals of New York Academy of Sciences 2000, 902:84-93. , discussion 93-94.
56. Farhat N., Matouk C.C., Mamarbachi A.M., Marsden P.A., Allen B.G., Thorin E. Activation of ETB receptors regulates the abundance of ET-1 mRNA in vascular endothelial cells. British Journal of Pharmacology 2008, 153:1420-1431.
57. Fecteau M.H., Honore J.C., Plante M., Labonte J., Rae G.A., D'Orleans-Juste P. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 2005, 46:87-92.
58. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
59. Galandrin S., Oligny-Longpre G., Bouvier M. The evasive nature of drug efficacy: Implications for drug discovery. Trends in Pharmacological Sciences 2007, 28:423-430.
60. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., Badesch D.B., McGoon M.D., McLaughlin V.V., Roecker E.B., Gerber M.J., Dufton C., Wiens B.L., Rubin L.J. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
61. Garcia-Villalon A.L., Amezquita Y.M., Monge L., Fernandez N., Salcedo A., Dieguez G. Endothelin-1 potentiation of coronary artery contraction after ischemia-reperfusion. Vascular Pharmacology 2008, 48:109-114.
62. Ge Y., Bagnall A., Stricklett P.K., Strait K., Webb D.J., Kotelevtsev Y., Kohan D.E. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. The American Journal of Physiology-Renal Physiology 2006, 291:F1274-F1280.
63. Gesty-Palmer D., Flannery P., Yuan L., Corsino L., Spurney R., Lefkowitz R.J., Luttrell L.M. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Science Translational Medicine 2009, 1:1ra1.
64. Glorioso N., Herrera V.L., Bagamasbad P., Filigheddu F., Troffa C., Argiolas G., Bulla E., Decano J.L., Ruiz-Opazo N. Association of ATP1A1 and dear single-nucleotide polymorphism haplotypes with essential hypertension: Sex-specific and haplotype-specific effects. Circulation Research 2007, 100:1522-1529.
65. Gregan B., Jurgensen J., Papsdorf G., Furkert J., Schaefer M., Beyermann M., Rosenthal W., Oksche A. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. The Journal of Biological Chemistry 2004, 279:27679-27687.
66. Griendling K.K., Sorescu D., Lassegue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:2175-2183.
67. Grinstein S., Rothstein A. Mechanisms of regulation of the Na+/H+ exchanger. The Journal of Membrane Biology 1986, 90:1-12.
68. Halcox J.P., Nour K.R., Zalos G., Quyyumi A.A. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circulation Research 2001, 89:969-976.
69. Hamilton C.A., Thorin E., McCulloch J., Dominiczak M.H., Reid J.L. Chronic exposure of bovine aortic endothelial cells to native and oxidized LDL modifies phosphatidylinositol metabolism. Atherosclerosis 1994, 107:55-63.
70. Harada N., Himeno A., Shigematsu K., Sumikawa K., Niwa M. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: Possible formation of an ETA-ETB receptor heterodimer. Cellular and Molecular Neurobiology 2002, 22:207-226.
71. Hasdai D., Mathew V., Schwartz R.S., Smith L.A., Holmes D.R.Jr., Katusic Z.S., Lerman A. Enhanced endothelin-B-receptor-mediated vasoconstriction of small porcine coronary arteries in diet-induced hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:2737-2743.
72. Haynes W.G., Webb D.J. Endothelium-dependent modulation of responses to endothelin-I in human veins. Clinical Science (London) 1993, 84:427-433.
73. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854.
74. He J.Q., Pi Y., Walker J.W., Kamp T.J. Endothelin-1 and photoreleased diacylglycerol increase L-type Ca2+ current by activation of protein kinase C in rat ventricular myocytes. Journal de Physiologie 2000, 524(Pt 3):807-820.
75. Herrera V.L., Ponce L.R., Bagamasbad P.D., VanPelt B.D., Didishvili T., Ruiz-Opazo N. Embryonic lethality in Dear gene-deficient mice: New player in angiogenesis. Physiological Genomics 2005, 23:257-268.
76. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: Benefit from selective bradycardic agents. British Journal of Pharmacology 2008, 153:1589-1601.
77. Himeno A., Shigematsu K., Taguchi T., Niwa M. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: Interaction in the recognition of endothelin-1 between ETA and ETB receptors. Cellular and Molecular Neurobiology 1998, 18:447-452.
78. Hosoda K., Nakao K., Hiroshi A., Suga S., Ogawa Y., Mukoyama M., Shirakami G., Saito Y., Nakanishi S., Imura H. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Letters 1991, 287:23-26.
79. Ihling C., Szombathy T., Bohrmann B., Brockhaus M., Schaefer H.E., Loeffler B.M. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001, 104:864-869.
80. Inada T., Fujiwara H., Hasegawa K., Araki M., Yamauchi-Kohno R., Yabana H., Fujiwara T., Tanaka M., Sasayama S. Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters. Journal of the American College of Cardiology 1999, 33:565-571.
81. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:2863-2867.
82. Inoue A., Yanagisawa M., Takuwa Y., Mitsui Y., Kobayashi M., Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. The Journal of Biological Chemistry 1989, 264:14954-14959.
83. Ivey M.E., Osman N., Little P.J. Endothelin-1 signalling in vascular smooth muscle: Pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008, 199:237-247.
84. Kang M., Walker J.W. Endothelin-1 and PKC induce positive inotropy without affecting pHi in ventricular myocytes. Experimental Biology and Medicine (Maywood) 2006, 231:865-870.
85. Katoh H., Terada H., Iimuro M., Sugiyama S., Qing K., Satoh H., Hayashi H. Heterogeneity and underlying mechanism for inotropic action of endothelin-1 in rat ventricular myocytes. British Journal of Pharmacology 1998, 123:1343-1350.
86. Kedzierski R.M., Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annual Review of Pharmacology and Toxicology 2001, 41:851-876.
87. Kelly R.A., Eid H., Kramer B.K., O'Neill M., Liang B.T., Reers M., Smith T.W. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. The Journal of Clinical Investigation 1990, 86:1164-1171.
88. Kenakin T. Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends in Pharmacological Sciences 2007, 28:407-415.
89. Kinlay S., Behrendt D., Wainstein M., Beltrame J., Fang J.C., Creager M.A., Selwyn A.P., Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001, 104:1114-1118.
90. Kirkby N.S., Hadoke P.W., Bagnall A.J., Webb D.J. The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house?. British Journal of Pharmacology 2008, 153:1105-1119.
91. Koh E., Morimoto S., Kim S., Nabata T., Miyashita Y., Ogihara T. Endothelin stimulates Na+/H+ exchange in vascular smooth muscle cells. Biochemistry International 1990, 20:375-380.
92. Kohno M., Horio T., Yokokawa K., Kurihara N., Takeda T. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3',5'-monophosphate. Hypertension 1992, 19:320-325.
93. Komukai K., Jin O.U., Morimoto S., Kawai M., Hongo K., Yoshimura M., Kurihara S. Role of Ca2+/calmodulin-dependent protein kinase II in the regulation of the cardiac L-type Ca2+ current during endothelin-1 stimulation. American Journal of Physiology Heart and Circulatory Physiology 2010, 298:H1902-H1907.
94. Kourembanas S., McQuillan L.P., Leung G.K., Faller D.V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. The Journal of Clinical Investigation 1993, 92:99-104.
95. LaDouceur D.M., Flynn M.A., Keiser J.A., Reynolds E., Haleen S.J. ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochemical and Biophysical Research Communications 1993, 196:209-215.
96. Laporte S., Denault J.B., D'Orleans-Juste P., Leduc R. Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor. Journal of Cardiovascular Pharmacology 1993, 22(Suppl. 8):S7-S10.
97. Le Monnier de Gouville A.C., Lippton H., Cohen G., Cavero I., Hyman A. Vasodilator activity of endothelin-1 and endothelin-3: Rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. The Journal of Pharmacology and Experimental Therapeutics 1990, 254:1024-1028.
98. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., Burnett J.C.Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. The New England Journal of Medicine 1991, 325:997-1001.
99. Li K., Stewart D.J., Rouleau J.L. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. Circulation Research 1991, 69:301-312.
100. Liu Y., Gutterman D.D. Vascular control in humans: Focus on the coronary microcirculation. Basic Research in Cardiology 2009, 104:211-227.
101. Liu J.L., Pliquett R.U., Brewer E., Cornish K.G., Shen Y.T., Zucker I.H. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2001, 280:R1906-R1913.
102. Loennechen J.P., Stoylen A., Beisvag V., Wisloff U., Ellingsen O. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. American Journal of Physiology. Heart and Circulatory Physiology 2001, 280:H2902-H2910.
103. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. The New England Journal of Medicine 1986, 315:1046-1051.
104. Luscher T.F., Yang Z., Tschudi M., von Segesser L., Stulz P., Boulanger C., Siebenmann R., Turina M., Buhler F.R. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circulation Research 1990, 66:1088-1094.
105. MacCarthy P.A., Grocott-Mason R., Prendergast B.D., Shah A.M. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist. Circulation 2000, 101:142-147.
106. MacLean M.R., McCulloch K.M., Baird M. Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. Journal of Cardiovascular Pharmacology 1994, 23:838-845.
107. Maemura K., Kurihara H., Morita T., Oh-hashi Y., Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 1992, 38(Suppl. 1):29-35.
108. Maguire J., Davenport A.P. Alternative pathway to endothelin-converting enzyme for the synthesis of endothelin in human blood vessels. Journal of Cardiovascular Pharmacology 2004, 44(Suppl 1):S27-S29.
109. Maguire J.J., Kuc R.E., Davenport A.P. Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro. British Journal of Pharmacology 2001, 134:1360-1366.
110. Mann J.F., Green D., Jamerson K., Ruilope L.M., Kuranoff S.J., Littke T., Viberti G. Avosentan for overt diabetic nephropathy. Journal of American Society of Nephrology 2010, 21:527-535.
111. Marsden P.A., Brenner B.M. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. The American Journal of Physiology 1992, 262:C854-C861.
112. Matsumura Y., Kuro T., Kobayashi Y., Konishi F., Takaoka M., Wessale J.L., Opgenorth T.J., Gariepy C.E., Yanagisawa M. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation 2000, 102:2765-2773.
113. McConnell P.I., Olson C.E., Patel K.P., Blank D.U., Olivari M.T., Gallagher K.P., Quenby-Brown E., Zucker I.H. Chronic endothelin blockade in dogs with pacing-induced heart failure: Possible modulation of sympathoexcitation. Journal of Cardiac Failure 2000, 6:56-65.
114. Motte S., McEntee K., Naeije R. Endothelin receptor antagonists. Pharmacology & Therapeutics 2006, 110:386-414.
115. Muramatsu M., Oka M., Morio Y., Soma S., Takahashi H., Fukuchi Y. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. The American Journal of Physiology 1999, 276:L358-L364.
116. Nelson M.T., Cheng H., Rubart M., Santana L.F., Bonev A.D., Knot H.J., Lederer W.J. Relaxation of arterial smooth muscle by calcium sparks. Science 1995, 270:633-637.
117. Newton A.C., Keranen L.M. Phosphatidyl-l-serine is necessary for protein kinase C's high-affinity interaction with diacylglycerol-containing membranes. Biochemistry 1994, 33:6651-6658.
118. Nguyen T.D., Vequaud P., Thorin E. Effects of endothelin receptor antagonists and nitric oxide on myogenic tone and alpha-adrenergic-dependent contractions of rabbit resistance arteries. Cardiovascular Research 1999, 43:755-761.
119. Ogawa Y., Nakao K., Arai H., Nakagawa O., Hosoda K., Suga S., Nakanishi S., Imura H. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochemical and Biophysical Research Communications 1991, 178:248-255.
120. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
121. Pierre L.N., Davenport A.P. Endothelin receptor subtypes and their functional relevance in human small coronary arteries. British Journal of Pharmacology 1998, 124:499-506.
122. Pieske B., Beyermann B., Breu V., Loffler B.M., Schlotthauer K., Maier L.S., Schmidt-Schweda S., Just H., Hasenfuss G. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 1999, 99:1802-1809.
123. Prins B.A., Hu R.M., Nazario B., Pedram A., Frank H.J., Weber M.A., Levin E.R. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. The Journal of Biological Chemistry 1994, 269:11938-11944.
124. Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., Gerard C., Lefkowitz R.J. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:628-632.
125. Reriani M., Raichlin E., Prasad A., Mathew V., Pumper G.M., Nelson R.E., Lennon R., Rihal C., Lerman L.O., Lerman A. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010, 122:958-966.
126. Resink T.J., Scott-Burden T., Buhler F.R. Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochemical and Biophysical Research Communications 1988, 157:1360-1368.
127. Richard V., Hogie M., Clozel M., Loffler B.M., Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995, 91:771-775.
128. Robu V.G., Pfeiffer E.S., Robia S.L., Balijepalli R.C., Pi Y., Kamp T.J., Walker J.W. Localization of functional endothelin receptor signaling complexes in cardiac transverse tubules. The Journal of Biological Chemistry 2003, 278:48154-48161.
129. Rosano L., Cianfrocca R., Masi S., Spinella F., Di Castro V., Biroccio A., Salvati E., Nicotra M.R., Natali P.G., Bagnato A. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:2806-2811.
130. Rossi G.P., Andreis P.G., Colonna S., Albertin G., Aragona F., Belloni A.S., Nussdorfer G.G. Endothelin-1[1-31]: A novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. The Journal of Clinical Endocrinology and Metabolism 2002, 87:322-328.
131. Rubanyi G.M., Polokoff M.A. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacological Reviews 1994, 46:325-415.
132. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. The New England Journal of Medicine 2002, 346:896-903.
133. Rubinstein I., Gurbanov K., Hoffman A., Better O.S., Winaver J. Differential effect of endothelin-1 on renal regional blood flow: Role of nitric oxide. Journal of Cardiovascular Pharmacology 1995, 26(Suppl. 3):S208-S210.
134. Ruiz-Opazo N., Hirayama K., Akimoto K., Herrera V.L. Molecular characterization of a dual endothelin-1/Angiotensin II receptor. Molecular Medicine 1998, 4:96-108.
135. Ruschitzka F., Moehrlen U., Quaschning T., Lachat M., Noll G., Shaw S., Yang Z., Teupser D., Subkowski T., Turina M.I., Luscher T.F. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease. Circulation 2000, 102:1086-1092.
136. Saida K., Mitsui Y., Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. The Journal of Biological Chemistry 1989, 264:14613-14616.
137. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
138. Sanchez R., MacKenzie A., Farhat N., Nguyen T.D., Stewart D.J., Mercier I., Calderone A., Thorin E. Endothelin B receptor-mediated regulation of endothelin-1 content and release in cultured porcine aorta endothelial cell. Journal of Cardiovascular Pharmacology 2002, 39:652-659.
139. Sato K., Oka M., Hasunuma K., Ohnishi M., Kira S. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. The American Journal of Physiology 1995, 269:L668-L672.
140. Sauvageau S., Thorin E., Caron A., Dupuis J. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Experimental Biology and Medicine (Maywood) 2006, 231:840-846.
141. Sauvageau S., Thorin E., Caron A., Dupuis J. Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. Journal of Vascular Research 2007, 44:375-381.
142. Sauvageau S., Thorin E., Villeneuve L., Dupuis J. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: Role of ETB-receptor expression levels. Pulmonary Pharmacology & Therapeutics 2009, 22:311-317.
143. Schneider M.P., Boesen E.I., Pollock D.M. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annual Review of Pharmacology and Toxicology 2007, 47:731-759.
144. Sen U., Tyagi N., Patibandla P.K., Dean W.L., Tyagi S.C., Roberts A.M., Lominadze D. Fibrinogen-induced endothelin-1 production from endothelial cells. American Journal of Physiology. Cell Physiology 2009, 296:C840-C847.
145. Shetty S.S., Okada T., Webb R.L., DelGrande D., Lappe R.W. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochemical and Biophysical Research Communications 1993, 191:459-464.
146. Simonson M.S., Dunn M.J. Cellular signaling by peptides of the endothelin gene family. The FASEB Journal 1990, 4:2989-3000.
147. Simpson A.W., Ashley C.C. Endothelin evoked Ca2+ transients and oscillations in A10 vascular smooth muscle cells. Biochemical and Biophysical Research Communications 1989, 163:1223-1229.
148. Sirvio M.L., Metsarinne K., Saijonmaa O., Fyhrquist F. Tissue distribution and half-life of 125I-endothelin in the rat: Importance of pulmonary clearance. Biochemical and Biophysical Research Communications 1990, 167:1191-1195.
149. Spinella F., Garrafa E., Di Castro V., Rosano L., Nicotra M.R., Caruso A., Natali P.G., Bagnato A. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Research 2009, 69:2669-2676.
150. Sprague A.H., Khalil R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochemical Pharmacology 2009, 78:539-552.
151. Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?. Annals of Internal Medicine 1991, 114:464-469.
152. Sumner M.J., Cannon T.R., Mundin J.W., White D.G., Watts I.S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. British Journal of Pharmacology 1992, 107:858-860.
153. Takahashi M., Matsushita Y., Iijima Y., Tanzawa K. Purification and characterization of endothelin-converting enzyme from rat lung. The Journal of Biological Chemistry 1993, 268:21394-21398.
154. Takahashi H., Soma S., Muramatsu M., Oka M., Ienaga H., Fukuchi Y. Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. The European Respiratory Journal 2001, 18:5-14.
155. Teerlink J.R., Breu V., Sprecher U., Clozel M., Clozel J.P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circulation Research 1994, 74:105-114.
156. Thomas G.P., Sims S.M., Karmazyn M. Differential effects of endothelin-1 on basal and isoprenaline-enhanced Ca2+ current in guinea-pig ventricular myocytes. Journal de Physiologie 1997, 503(Pt. 1):55-65.
157. Thorin E. Different contribution of endothelial nitric oxide in the relaxation of human coronary arteries of ischemic and dilated cardiomyopathic hearts. Journal of Cardiovascular Pharmacology 2001, 37:227-232.
158. Thorin E., Hamilton C., Dominiczak A.F., Dominiczak M.H., Reid J.L. Oxidized-LDL induced changes in membrane physico-chemical properties and [Ca2+]i of bovine aortic endothelial cells. Influence of vitamin E. Atherosclerosis 1995, 114:185-195.
159. Thorin E., Lucas M., Cernacek P., Dupuis J. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. American Journal of Physiology. Heart and Circulatory Physiology 2000, 279:H844-H851.
160. Thorin E., Nguyen T.D., Bouthillier A. Control of vascular tone by endogenous endothelin-1 in human pial arteries. Stroke 1998, 29:175-180.
161. Thorin E., Parent R., Ming Z., Lavallee M. Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. The American Journal of Physiology 1999, 277:H524-H532.
162. Thorin E., Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovascular Research 2009, 84:24-32.
163. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Horie H., Sugimoto Y., Kinoshita M. Transcardiac extraction of circulating endothelin-1 across the failing heart. The American Journal of Cardiology 2000, 86:524-528.
164. Unoki H., Fan J., Watanabe T. Low-density lipoproteins modulate endothelial cells to secrete endothelin-1 in a polarized pattern: A study using a culture model system simulating arterial intima. Cell and Tissue Research 1999, 295:89-99.
165. Vanhoutte P.M., Rubanyi G.M., Miller V.M., Houston D.S. Modulation of vascular smooth muscle contraction by the endothelium. Annual Review of Physiology 1986, 48:307-320.
166. Verhaar M.C., Strachan F.E., Newby D.E., Cruden N.L., Koomans H.A., Rabelink T.J., Webb D.J. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998, 97:752-756.
167. Vierhapper H., Wagner O., Nowotny P., Waldhausl W. Effect of endothelin-1 in man. Circulation 1990, 81:1415-1418.
168. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends in Pharmacological Sciences 2007, 28:416-422.
169. Watanabe T., Endoh M. Antiadrenergic effects of endothelin-1 on the L-type Ca2+ current in dog ventricular myocytes. Journal of Cardiovascular Pharmacology 2000, 36:344-350.
170. Watts S.W. Endothelin receptors: What's new and what do we need to know?. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2010, 298:R254-R260.
171. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy S.K., Lefkowitz R.J. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16657-16662.
172. Yanagisawa M., Inoue A., Ishikawa T., Kasuya Y., Kimura S., Kumagaye S., Nakajima K., Watanabe T.X., Sakakibara S., Goto K., et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:6964-6967.
173. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
174. Yorikane R., Koike H. The arrhythmogenic action of endothelin in rats. Japanese Journal of Pharmacology 1990, 53:259-263.
175. Yorikane R., Shiga H., Miyake S., Koike H. Evidence for direct arrhythmogenic action of endothelin. Biochemical and Biophysical Research Communications 1990, 173:457-462.
176. Yu C., Yang Z., Ren H., Zhang Y., Han Y., He D., Lu Q., Wang X., Yang C., Asico L.D., Hopfer U., Eisner G.M., Jose P.A., Zeng C. D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. American Journal of Hypertension 2009, 22:877-883.
177. Zeng C., Asico L.D., Yu C., Villar V.A., Shi W., Luo Y., Wang Z., He D., Liu Y., Huang L., Yang C., Wang X., Hopfer U., Eisner G.M., Jose P.A. Renal D3 dopamine receptor stimulation induces natriuresis by endothelin B receptor interactions. Kidney International 2008, 74:750-759.